Conventional treatment group | Mastication intervention group | |||||
---|---|---|---|---|---|---|
Measurements | Baseline (n = 12) | After 6 months (n = 12) | p value | Baseline (n = 16) | After 6 months (n = 16) | p value |
Weight (kg) | 93.6 ± 12.8 | 89.8 ± 13.9 | 0.005* | 88.1 ± 20.5 | 82.3 ± 18.1 | 0.030* |
Body fat percentage (%) | 47.7 ± 4.7 | 47.2 ± 5.2 | 0.729 | 47.7 ± 3.9 | 45.0 ± 4.8 | < 0.001** |
BMI (kg/m2) | 37.4 ± 5.2 | 35.8 ± 5.5 | 0.003* | 36.9 ± 6.7 | 33.8 ± 6.1 | < 0.001** |
Skeletal muscle mass (kg) | 26.1 ± 3.2 | 25.6 ± 3.1 | 0.005* | 25.4 ± 4.8 | 24.3 ± 4.5 | < 0.001** |
Body fat (kg) | 45.6 ± 8.6 | 42.6 ± 10.3 | 0.016* | 43.3 ± 12.5 | 37.6 ± 11.6 | < 0.001** |
Subcutaneous fat area (cm2) | 497.0 ± 133.7 | 408.8 ± 166.4 | 0.015* | 429.1 ± 159.3 | 391.5 ± 157.2 | 0.154 |
Visceral fat area (cm2) | 161.8 ± 67.6 | 135.1 ± 93.2 | 0.041* | 175.6 ± 64.9 | 150.7 ± 60.7 | 0.019* |
HbA1c (%) | 5.8 (5.5–6.1) | 5.8 (5.4–5.9) | 0.027*,† | 6.0 ± 0.6 | 5.8 ± 0.5 | 0.014* |
AST (IU/L) | 21.50 (17.8–31.3) | 18.0 (16.0–24.5) | 0.020*,† | 30.0 (17.0–35.8) | 18.0 (17.0–24.8) | 0.022*,† |
ALT (IU/L) | 28.0 (17.8–39.3) | 16.5 (14.0–29.8) | 0.008*,† | 36.5 (20.3–55.3) | 22.0 (15.8–36.3) | 0.008**,† |
GGT (IU/L) | 32.5 ± 15.2 | 24.6 ± 10.1 | 0.005** | 37.6 ± 17.2 | 25.1 ± 12.9 | 0.002** |
FPG (mg/dL) | 104.5(91.3–109.0) | 99.5 (95.8–106.5) | 0.929† | 107.4 ± 17.2 | 98.1 ± 12.5 | 0.007** |
TG (mg/dL) | 110.5(82.5–162.3) | 91.5 (73.5–131.0) | 0.002*,† | 116.5(76.3-224.8) | 87.0 (61.0–129.3) | 0.059† |
HDL (mg/dL) | 45.4 ± 9.5 | 57.4 ± 15.1 | < 0.001** | 41.0 (35.0–49.0) | 48.5 (43.3–56.5) | 0.001**,† |
LDL (mg/dL) | 113.0 ± 28.3 | 126.0 ± 20.9 | 0.049* | 111.1 ± 33.1 | 119.8 ± 31.3 | 0.013* |
IRI (µU/mL) | 11.0 (7.1–21.3) | 14.9 (10.0–24.7) | 0.272† | 12.5 (9.1–18.2) | 9.9 (6.2–16.9) | 0.215† |
HOMA-R | 3.8 ± 2.3 | 4.2 ± 1.9 | 0.551 | 3.7 (2.1–3.9) | 2.2 (1.5–4.0) | 0.109† |